Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
Patients with end-stage renal failure have a markedly higher mortality because of
cardiovascular events in comparison with the normal population. Disorders in the calcium
metabolism, such as calcification of the vessel walls, occur very frequently. There are
indications that calcium channel blockers are capable of lowering the cardiovascular
mortality in patients with end-stage renal failure.
It is intended to carry out a prospective, randomized, double-blind, placebo-controlled,
multicenter study in order to find out if the calcium channel blocker amlodipine is able to
reduce the mortality of patients with end-stage renal failure.
The investigation will be carried out after suitable explanation and written informed consent
in 356 patients aged between 18 and 90 years with end-stage renal failure and chronic
haemodialysis treatment. The patients will be randomized to either treatment with amlodipine
10 mg/day or placebo. The occurrence of events will be documented and evaluated prospectively
over a period of 30 months.